期刊文献+

慢性心力衰竭患者不同方法治疗前后纤维化指标初步观察

Comparison for contents of index of fibrosis before and after treatment in patients with chronic heart failure
下载PDF
导出
摘要 目的 :比较不同心功能级数慢性心力衰竭 (CHF)患者治疗前后血清Ⅲ型前胶原 (PCⅢ )、透明质酸 (HA)和层粘蛋白(LN)含量的变化 ,研究心肌纤维对该病的影响。方法 :用放射免疫法对 84例慢性心力衰竭 (CHF)患者血清PCⅢ ,HA和LN含量进行测定。结果 :84例CHF患者血清PCⅢ ,HA和LN含量分别为 ( 180 3 3± 3 2 5 6) μg·L-1,( 88 2 5± 2 9 14) μg·L-1和( 13 2 45± 2 6 3 3 ) μg·L-1,与正常对照组比较有显著性差异 (P均 <0 0 1) ;心功能Ⅱ级和Ⅲ级患者上述纤维 3项指标水平明显高于心功能Ⅰ级者 (P <0 0 5 ) ,且升高程度与心功能级数相平行 ;不同心功能级数CHF患者血清PCⅢ ,HA和LN纤维 3项指标含量治疗后较治疗前明显降低 (P <0 0 5~ 0 0 1)。结论 :CHF患者PCⅢ ,HA和LN含量升高 ,可能与心功能有关 。 AIM: To detect contents of type Ⅲ prophase-collagen (PCⅢ), hyaluronic acid (HA) and laminin (LN) in different function degree before and after treatment in patients with chronic heart failure (CHF) and to research myocardial the fiber to influence that disease. METHODS: Radioimmunoassay (RIA) was used to measure the changes of the serum contents of PCⅢ, HA and LN of 84 examples of CHF. RESULTS: The contents of PCⅢ, HA and LN in 84 patients with CHF were (180.33±32.56) μg·L -1, (88.25±29.14) μg·L -1 and (132.45±26.33) μg·L -1, respectively, obviously higher than those of the normal (P<0.01); Heart function stageⅡ and stageⅢ were obvious higher than heart function stageⅠ (P<0.05). It was found that above contents were paralleled with degree and heart function stage for distinct heart function degree of CHF, the index of fibrosis cut down obviously after treatment (P<0.05-0.01). CONCLUSION: The results show that the obvious rise of PCⅢ, HA and LN in CHF patients is related to heart function. The antifibrosis treatment of CHF has positive therapeutic effect by the myocardial antifibrosis.
出处 《中国临床药学杂志》 CAS 2003年第3期139-141,共3页 Chinese Journal of Clinical Pharmacy
关键词 慢性心力衰竭患者 治疗 纤维化指标 心肌纤维化 放射免疫法 chronic heart failure myocardial fibrosis treatment radioimmunoassay
  • 相关文献

参考文献4

二级参考文献22

  • 1Coats Andrew J S. Initiating therapy in heart failure. 2 nd ed. Dartfor: Magister Consulting Ltd,1998.24-34.
  • 2Opie LH. Angiotensin converting enzyme inhibitors. 2 nd ed. New York: Authors Publishing House, 1994.197-201.
  • 3Grandi Am, Venco A, Barzizza F, et al. Double-blind comparison of perindopril and captopril in hypertension: effects on left ventricular morphology and function. Am J Hypertens,1991,4:516-526.
  • 4Asmar RG, Journo HJ, Lacolley PJ, et al. Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. J Hypertens,1988,6(Suppl 3):s33-39.
  • 5Cheorghiade M, Cody RJ, Francis GS,et al. Current medical therapy for advanced heart failure. Am Heart J,1998,132(Suppl):s231-248.
  • 6Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.The SOLVD Investigators. N Engl J Med, 1991,325:293-302.
  • 7Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).The CONSENSUS Trial Study Group. N Engl J Med,1987,316:1429-1435.
  • 8Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee on Evaluation and Management of Heart Failure). Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol,1995,26:1376-1398.
  • 9Sharpe N, Murphy J, Smith H, et al. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet, 1988,1:255-259.
  • 10Sharpe N, Smith H, Murphy J, et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting- enzyme inhibition. Lancet, 1991,337:872-876.

共引文献466

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部